Ebola vaccines, therapies, and diagnostics

Vaccines in development

Results from Phase I clinical trials for two vaccine candidates – ChAd3-ZEBOV, developed by GlaxoSmithKline (GSK) in collaboration with the US National Institute of Allergy and Infectious Diseases (NIAID), and VSV-EBOV, developed by NewLink Genetics and Merck Vaccines USA in collaboration with the Public Health Agency of Canada – were obtained in January. Both vaccine candidates have been shown to be safe and well tolerated in humans. The results from the trials were published in the New England Journal of Medicine.

Is there a vaccine licensed to protect against Ebola virus disease?

At this time, there are no vaccines to protect against EVD licensed for use in humans. Clinical trials for several candidate vaccines are in various phases and a safe and effective vaccine is hoped for by the end of 2015.

  

Which vaccines are being tested and where?

Product / Company	Phase	Trial Location	Dates
ChAd3-ZEBOV GlaxoSmithKline and PHAC	Phase I	By VRC at NIH, USA	September 2014
		By Oxford University in the UK
		By CVD in Mali	October 2014
		At the University of Lausanne, Lausanne, Switzerland
rVSV-ZEBOV NewLink Genetics and Merck Vaccines USA	Phase I	By WRAIR in the US	October 2014
		By NIAID in the US
		By CTC North GmbH in Hamburg, Germany	November 2014
		At Albert Schweitzer Hospital in Lambarene, Gabon
		At the University of Geneva, Geneva, Switzerland
		At the IWK Health Center, Halifax, Canada
		By KEMRI Wellcome Trust in Kilifi, Kenya	December 2014
Ad26-EBOV and MVA-EBOV Johnson & Johnson and Bavarian Nordic	Phase I	By University of  Oxford in the UK and NIAID, USA	January 2015
		TBD, Kenya	Second half of 2015
		TBD, Uganda
		TBD, United Republic of Tanzania
Recombinant protein Ebola vaccine candidate Novavax	Phase I	Australia	February 2015
ChAd3-ZEBOV GlaxoSmithKline and PHAC	Phase II	TBD, Cameroon	Second half of 2015
		TBD, Ghana
		TBD, Mali
		TBD, Nigeria
		TBD, Senegal
VSV-EBOV NewLink Genetics and Merck Vaccines USA	Phase III	By WHO, Médecins Sans Frontiéres (MSF) and Government of Guinea in Conakry, Guinea	April 2015 – Ring vaccination trial design. As of 17 July, 103 rings comprising approximately 4 000 volunteers have been vaccinated.
VSV-EBOV	Phase III	By Médecins Sans Frontiéres (MSF),  WHO and Government of Guinea in Conakry, Guinea	March 2015 – A vaccine trial for front line workers only. As of 19 June, more than 800 volunteers have been vaccinated. The target number is 1 200.
ChAd3-ZEBOV GlaxoSmithKline and PHAC and VSV-EBOV NewLink Genetics and Merck Vaccines USA	Phase II/III	By US NIH and MOH Liberia in Monrovia, Liberia	March 2015 – Randomized control trial design As of 30 April, Phase II enrollment of 1 500 volunteers in Liberia was completed.
VSV-EBOV NewLink Genetics and Merck Vaccines USA	Phase III	By US CDC and MOH Sierra Leone in Freetown, Sierra Leone	April 2015 – Cluster based, non-blinded, individually randomized trial design. As of 18 June, approximately 6 000 frontline workers had been enrolled with half of them vaccinated.